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Introduction
The rate of surgical site infection (SSI) for clean dermatologi-
cal surgery is usually less than 3% [1-3], which is significantly 
lower than the 5% acceptable SSI rate quoted by many 
authorities [4,5]. The incidence of SSI is influenced by body 
site, and certain anatomical sites are at much higher risk than 
the acceptable rate [6-9], with lower limb surgery most con-
sistently complicated by infection [3,10-16]. In tropical North 
Queensland, the infection rates following excisions from the 
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Background: Surgical site infection (SSI) rates for below-knee dermatological surgery are unaccept-
ably high, particularly following complex flap and graft closures. The role of antibiotic prophylaxis 
for these surgical cases is uncertain.
Objective: To determine whether SSI following complex dermatological closures on the leg could be 
reduced by antibiotic prophylaxis administered as a single oral preoperative dose.
Methods: A total of 115 participants were randomized to 2 g of oral cephalexin or placebo 40-60 
minutes prior to surgical incision in a prospective, randomized, double-blind, placebo-controlled trial 
at a primary care skin cancer clinic in North Queensland, Australia.
Results: Overall 17/55 (30.9%) controls and 14/55 (25.5%) intervention participants developed in-
fection (P = 0.525). There was no difference between the study groups in adverse symptoms that could 
be attributed to high-dose antibiotic administration (P = 1).
Conclusion: A single oral 2-g dose of cephalexin given before complex below-knee dermatological 
closure did not reduce SSI.
ABSTRACT
Research  |  Dermatol Pract Concept 2019;9(1):8 29
Despite the importance of this topic, 
few randomized controlled trials (RCTs) 
have been published on the use of oral 
antibiotic prophylaxis in dermatological 
surgery [17]. The aim of our random-
ized, double-blind, placebo-controlled 
trial was to ascertain the effect of a 
single preoperative oral prophylactic 
antibiotic dose on SSI following com-
plex below-knee dermatological surgery.
Methods
This randomized, double-blind, pla-
cebo-controlled trial recruited consecu-
tive eligible patients booked for flap 
or graft closure following skin cancer 
excision below the knee at a primary 
care skin cancer clinic in Townsville, 
North Queensland, Australia, between 
January 2014 and February 2016. Each 
individual patient gave signed informed 
consent and was allowed to participate 
in the trial only once.
Specific exclusion criteria (Figure 
1) were age under 18, taking any anti-
biotic within 48 hours of the surgery, 
suspected SSI at the time of surgery, 
allergy to the protocol suture, dressing 
materials, cephalosporins or penicillin, 
intellectual or mental impairment, and 
previous participation in this study. If 
histology confirmed the need for a wider 
excision or participants received antibi-
otics for another SSI during the 30-day 
study period, participants were to be 
withdrawn from the study.
lower limb have ranged from 14.75% 
to 18.18% [13,16]. Below-knee surgery 
has been shown to have an even higher 
infection rate [13,16,17]. The reasons 
for this are unclear, but reduced perfu-
sion pressure in the distal limbs [18], 
higher tension closures [19], as well as 
the frequent necessity for complex graft/
flap surgery are postulated reasons.
More complex skin closures, such 
as flap and graft procedures, are known 
also to be independently associated with 
significantly higher risk of SSI [20]. 
Large observational prospective studies 
have shown that flap repair increases 
the likelihood of infection by 2 to 15 
times compared with simple elliptical 
closure [3,18,20,21]. Graft repair has 
also been linked to much higher infec-
tion rates [3,18,20,21].
Established SSI may require mul-
tiple medical visits, can result in poorer 
cosmetic outcome and significant bac-
teremic complications [8,17], and also 
requires several days of treatment with 
antibiotics. Antibiotic treatment may 
be associated with unpleasant side 
effects, allergy, and the development of 
antibiotic resistance [8]. As a result of 
indiscriminate antibiotic prescribing, 
antibiotic resistance is increasing at a 
dramatic rate, causing significant mor-
bidity and mortality globally [22,23]. A 
single, high-dose preoperative oral pro-
phylactic antibiotic has been proposed 
for anatomical sites and dermatological 
procedures at high risk of SSI [8]. It is 
suggested that administration of such 
a single prophylactic dose may be less 
likely to result in antibiotic resistance 
than a longer-term course prescribed for 
established infection, with a resulting 
reduction in the quantity of antibiotics 
prescribed overall [17,19,24].
If antibiotic prophylaxis is to be 
effective, antibiotics should optimally 
be in the bloodstream and at the opera-
tive site at the time of incision [25,26]. 
The administration of antibiotics within 
2 hours prior to incision is associated 
with the lowest risk of SSI [26].
Figure 1. Inclusion and exclusion criteria for study. [Copyright: ©2019 Rosengren et al.]
Capsules containing either 2 g of 
cephalexin or placebo were given 30 
minutes prior to the excision appoint-
ment time, ensuring that skin incision 
would be within 60 minutes of inges-
tion of capsules. At the time of surgery 
baseline demographic data, pertinent 
medical and drug history, defect size, 
time from intervention to incision, and 
closure technique were documented. 
Histology was documented once it had 
been reported.
Intra- and Postoperative Protocol
If the wound required deep dermal 
absorbable sutures, Monosyn (B. Braun, 
Sydney, Australia) was used. All defects 
were closed superficially with nylon 
sutures (Dynek Pty Ltd., Hendon, South 
Australia). Following wound closure, 
Melolin (Smith and Nephew Medical 
Ltd, Hull, UK) and Fixomull (BSN Med-
ical, Luxenburg) was applied.
Standardized verbal and written 
postoperative wound care instructions 
were given to all participants, stressing 
the importance of applying no topi-
cal creams, ointments, or antiseptics to 
the wound for the month after surgery. 
All participants were reviewed 7 days 
postoperatively for wound inspection 
and redressing. Information related to 
the use of postoperative oral analge-
sia (strongest analgesic used) was also 
recorded at this time. Early review at 
the study practice was encouraged in the 
event of discomfort, erythema, swelling, 
or discharge associated with the wound. 
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t test, chi-square test, and Fisher exact 
test. Intervention and control group dif-
ferences at baseline as well as treatment 
modality differences were assessed using 
unpaired t test, Mann-Whitney test, chi-
square test, and Fisher exact test.
All data were analyzed using inten-
tion-to-treat analysis. Incidence of SSI 
was compared between intervention 
and control groups using chi-square 
test. The difference in infection rate was 
calculated and presented with 95% con-
fidence interval (95% CI). The number 
needed to treat for benefit was calcu-
lated with 95% CI [29]. A sensitivity 
analysis was conducted including all 
115 patients who were originally ran-
domized by assuming various outcome 
scenarios for the 5 patients who were 
lost to follow-up. Logistic regression 
models were applied to assess poten-
tial confounding effects of all baseline 
characteristics on difference in incidence 
of infection between intervention and 
control groups.
Chi-square and Fisher exact tests 
were used to compare postoperative 
analgesia requirements, adverse effects, 
and treatment of occurring infections 
between intervention and control 
groups.
Analysis was conducted using Sta-
taIC12 (StataCorp LP, Lakeway Drive, 
College Station, TX, USA). A P value less 
than 0.05 was considered statistically 
significant.
capsules filled with either antibiotic 
(intervention) or placebo (control) 
were transferred to screw-top containers 
numbered according to the randomiza-
tion sequence and sent to the recruit-
ing practice in batches. Clinic staff and 
participants remained blind to group 
allocation during the trial.
Sample Size
A small prestudy observational trial at 
the practice had shown approximately 
25% infection rates for flap and graft 
closures below the knee. Our hypothesis 
was that antibiotic prophylaxis would 
reduce the infection rate to 5%. Forty-
four patients were required in each 
study group to show this with statisti-
cal confidence (power in excess of 80%; 
significance level 0.05). We planned to 
recruit a minimum of 110 participants 
(55 intervention and 55 placebo), allow-
ing for a 25% drop out.
Statistical Analysis and 
Presentation
Statistical analysis and result prepara-
tion followed the CONSORT guidelines 
[28]. Numerical data were described 
using mean and standard deviation 
when symmetrically distributed and 
median and interquartile range when 
skewed. Categorical data were presented 
using absolute and relative frequencies.
Eligible nonparticipants were com-
pared with participants using unpaired 
Sutures were removed 14 days after 
surgery. If at the time of suture removal 
the wound had not fully healed, it was 
dressed again and regularly reviewed 
until it had completely epithelialized.
Clinical Outcome
The wound was assessed at the time 
of suture removal (14 days postopera-
tively) by 1 of the 6 treating doctors. 
An adapted version of the 1988 Centers 
of Disease Control and Prevention of 
National Nosocomial Infections Surveil-
lance System definition for dermato-
logical surgical site infection was used 
[27]. Standardized criteria for surgical 
site skin infection included occurrence 
within 30 days of surgery and puru-
lent discharge, erythema more than 1 
cm from wound edges, OR presence of 
localized swelling, heat, pain, or tender-
ness (Figure 2).
If SSI was suspected, a swab was 
taken for microscopy, culture, and sen-
sitivity and a 5-day course of cephalexin 
(500 mg 4 times a day) was prescribed 
pending swab results. Each participant 
was phoned by the study nurse 1 month 
after surgery to ensure no SSI was inad-
vertently missed.
Randomization and Blinding
The randomization sequence was gen-
erated electronically using IBM SPSS 
Statistics (V 22.0, IBM Corp., Armonk, 
NY, USA) by author and statistician 
(P.G.B.) and emailed to a compound-
ing pharmacy where batches of generic 
gel capsules had been filled with either 
cephalexin or placebo (microcrystal-
line cellulose and calcium carbonate 
powder). Four identical-looking gel Figure 3. CONSORT Flow Diagram for Trial. [Copyright: ©2019 Rosengren et al.]
Figure 2. Criteria for surgical site infec-
tion in dermatological surgery. [Copyright: 
©2019 Rosengren et al.]
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during the study follow-up period. Three 
participants (2 controls, 1 intervention) 
were lost to follow-up despite repeated 
attempts at phone contact. There were 
no demonstrable differences between 
the characteristics of the 5 participants 
who did not complete the study and the 
110 who did.
Surgical Site Infection
The main analysis based on available 
cases at follow-up (Table 3) showed 17 
(30.9%; n = 55) SSIs for control and 14 
(25.5%; n = 55) for intervention partici-
pants (P = 0.525). A sensitivity analysis 
including all 115 initially randomized 
patients did not alter this result, regard-
less of whether the patients who were 
lost to follow-up were assumed to have 
had an infection or not to have had an 
infection (Table 3). Logistic regression 
analyses to assess effects of possible 
confounding variables did not alter the 
main result of the trial. Only 1 (interven-
tion) of 8 split thickness graft closures 
developed SSI. All other cases of SSI 
occurred in flap closures.
The difference in infection rate 
between the control and intervention 
groups was 5.4% (95% CI: 11.4%-
22.2%). Nineteen patients needed to 
be treated (number needed to benefit) 
to prevent an infection. The power to 
detect the 5.4% difference in infection 
rates between intervention and con-
trol groups was 9.6%. A sample size of 
1,089 participants in each group would 
have been needed to reach a power of 
80%.
Secondary Outcome Measures
There was no difference in analgesia 
requirement between study groups, with 
the majority of participants (81.8% of 
controls; 78.2% of intervention group) 
taking no postoperative analgesia (Table 
4). One patient in the intervention group 
reported nausea in the follow-up period. 
No other symptoms that might have 
been attributable to the intervention 
were recorded in either study group.
Of the 115 participants, 57 were 
randomized to administration of pla-
cebo (control group) and 58 to admin-
istration of cephalexin (intervention 
group). The 2 study groups were com-
parable at baseline for all variables mea-
sured (age, sex, diabetes, smoking status, 
anticoagulant or immunosuppressive 
medication, anatomical site and histol-
ogy of tumor, defect size, and repair 
technique) (Table 2). Defect closure was 
with flap repair for 106 (52 control, 
55 intervention) participants and graft 
repair for 8 (5 control, 3 intervention) 
participants. The remaining participant 
had an elliptical closure. Graft repair in 
all cases was with split thickness skin 
taken from the area surrounding the 
defect. This method of graft closure is 
referred to as a halo graft [30].
Two participants (both intervention) 
violated protocol and were withdrawn 
from the study, one because the treating 
doctor opted to close the defect with an 
ellipse and the other because of needing 
antibiotic treatment for an unrelated SSI 
Results
Sixteen of 152 consecutive patients 
requiring flap or graft closures below 
the knee were ineligible for this study 
because of penicillin or cephalosporin 
allergy (n = 9), taking antibiotics for 
unrelated reasons at the time of surgery 
(n = 4), and previous participation in 
this study (n = 3).
Twenty-one eligible patients declined 
to participate. The most common rea-
sons given for nonparticipation were 
not wanting to take unnecessary tablets 
(n = 12) and fear of possible diarrhea (n 
= 3). Other reasons given (n = 6) were 
being too old, fear of allergy, and being 
unwell on the day of the procedure.
With the exception of site tumor, 
there was no difference between eligible 
nonparticipants and participants (Table 
1). Nonparticipants were more likely to 
have the neoplasm on the anterior leg 
whereas participants were more likely to 
have it on the calf (P = 0.030) (Table 1).
Table 1. Comparison of Nonparticipants Who Fulfilled In-
clusion Criteria With Those Participating in the Study
Characteristic
Nonparticipants 
(n = 21)
Participants 
(n = 115)
P Value
Mean age (SD), years 71.9 (12.4) 69.4 (10.8) 0.336
Male (%) 10 (47.6%) 73 (63.5%) 0.171
Body site of lesion (%)
 Foot
 Ankle
 Anterior leg
 Calf
1 (4.8%)
1 (4.8%)
15 (71.4%)
4 (19.0%)
8 (7.0%)
6 (5.2%)
44 (38.3%)
57 (49.6%)
0.030
Histologya (%)
 BCC
 SCC
 Keratoacanthoma
 Melanoma
6 (30.0%)
11 (55.0%)
2 (10.0%)
1 (5.0%)
54 (47.0%)
48 (41.7%)
7 (6.1%)
6 (5.2%)
0.059
Active smokera (%) 0 2 (1.7%) 1.0
Type 2 diabetes mellitusa (%) 1 (5.0%) 13 (11.3%) 0.693
User of anticoagulant 
medicationa (%)
0 27 (23.5%) 0.065
User of immunosuppressive 
medicationa (%)
0 1 (0.9%) 1.0
BCC = basal cell carcinoma; SCC = squamous cell carcinoma; SD = standard deviation.
a Missing information for 1 nonparticipant.
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Swab Results for SSI Cases
All patients with clinical SSI were 
treated with antibiotics, the majority 
(16/17 controls and 12/14 interven-
tion participants) receiving cephalexin 
(Table 4).
Doctors forgot to take swabs for 
microscopy, culture, and sensitivity in 
5 participants presenting to the study 
clinic with suspected SSI. A further 5 
study participants presented to clini-
cians elsewhere (hospital in 2 cases, own 
family doctor in 3 cases) with suspected 
SSI and were treated with antibiotics 
without first taking swabs.
Of the 10 participants (5 control, 
5 intervention) with suspected SSI 
not confirmed on microscopy, 8 were 
treated with cephalexin and 1 with 
dicloxacillin. In the final case, we were 
unable to ascertain what antibiotic had 
been prescribed. Clinical SSI settled in 
all 10 cases without the need for further 
intervention.
Of the 21 swabs taken, 12 (8 control, 
4 intervention) grew Staphylococcus 
aureus sensitive to cephalexin, 1 (inter-
vention) produced Stenotrophomonas 
maltophilia sensitive to cephalexin, and 
a further 4 (2 control, 2 intervention) 
developed no organism. Clinical SSI in 
all of these 17 swabbed cases responded 
fully to cephalexin which had been pre-
scribed.
Table 2. Baseline Comparison of Control Group 
(n = 57) With Intervention Group (n = 58)
Characteristic
Control  
(n = 57)
Intervention  
(n = 58)
P Value
Mean age (SD), years 69.4 (11.6) 69.4 (10.1) 0.982
Male (%) 34 (59.6%) 39 (67.2%) 0.398
Body site of lesion (%)
 Foot
 Ankle
 Anterior leg
 Calf
3 (5.3%)
2 (3.5%)
21 (36.8%)
31 (54.4%)
5 (8.6%)
4 (6.9%)
23 (39.7%)
26 (44.8%)
0.633
Histology (%)
 BCC
 SCC
 Keratoacanthoma
 Melanoma
30 (52.6%)
18 (33.4%)
5 (8.8%)
3 (5.3%)
24 (41.4%)
29 (50%)
2 (3.4%)
3 (5.2%)
0.412
Active smoker (%) 1 (1.8%) 1 (1.7%) 1.0
Type 2 diabetes mellitus (%) 7 (12.3%) 6 (10.3%) 0.777
User of anticoagulant 
medication (%)
10 (17.6%) 17 (29.3%) 0.248
Repair technique 
 Ellipse
 ROM flap
 Keystone flap
 Rotation
 A-T flap
 Other transposition flap
 Other advancement flap
 Split thickness (halo) graft
0
31 (54.4%)
6 (10.5%)
6 (10.5%)
6 (10.5%)
2 (3.5%)
1 (1.8%)
5 (8.8%)
1 (1.7%)a
28 (48.3%)
7 (12.1%)
7 (12.1%)
8 (13.8%)
3 (5.2%)
1 (1.7%)
3 (5.2%)
0.970
Median average diameter 
defect size
20.0 20.0 0.335
(IQR), mm (16, 22) (16, 24.5)b
BCC = basal cell carcinoma; IQR = interquartile range; SCC = squamous cell carcino-
ma; SD = standard deviation; ROM = reducing opposed multilobed flap.
a Patient receiving ellipse repair technique was removed from follow-up.
b Based on 57 patients.
Table 3. Sensitivity Analysis of Surgical Site Infection by Intention to Treat
Control Group
Intervention 
Group
Difference: 
Control Minus 
Intervention
Two-Sided  
95% CI
P Value
Participants who completed 
follow-up
17/55
(30.9%)
14/55
(25.5%)
5.4% −11.4, 22.2 0.525
Sensitivity analysis 
  Assuming all lost to follow-
up did not develop SSI
17/57
(29.8%)
14/58
(24.1%)
5.7% −10.5, 21.9 0.492
  Assuming all lost to follow-
up did develop SSI
19/57
(33.3%)
17/58
(29.3%)
4.0% −12.9, 20.9 0.642
CI = confidence interval; SSI = surgical site infection.
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rate of 12.5% in the intervention group, although this study 
was underpowered to produce statistical significance [17]. 
Our study differed in that we included only below-knee exci-
sions, which are at higher risk than the entire lower limb, and 
flap and graft surgery, which are at higher infection risk than 
ellipse excisions.
Other studies examining antibiotic prophylaxis for surgi-
cal sites elsewhere have also demonstrated the effectiveness 
of antibiotic prophylaxis, in contrast with our study. Two 
RCTs—one involving flap and graft repairs in a dermatologi-
cal surgery setting [31] and the other involving ear and nose 
only [32]—confirmed that single-dose oral antibiotic prophy-
laxis prevented SSI. Although a further RCT involving graft 
repairs on the nose was underpowered to show a reduction 
in SSI, graft survival was better for those randomized to anti-
biotic prophylaxis [33]. A recent meta-analysis of 12 RCTs 
studying antibiotic prophylaxis in dermatological surgery 
demonstrated that preoperative antibiotic prophylaxis was 
effective in preventing SSI and furthermore that single antibi-
otic use is of adequate efficacy and safety for preventing SSI 
[34]. It should be noted, however, that only 2 of these RCTs 
investigated oral antibiotic prophylaxis, with intravenous 
antibiotics investigated in the remaining 10 studies [34].
In 4 participants with SSI, the infection did not respond 
to cephalexin. Swabs in 2 cases (1 intervention, 1 control) 
isolated organisms not sensitive to cephalexin (Pseudomonas 
aeruginosa in one case, Enterobacter cloacae in the other). 
In a further 2 participants (1 control, 1 intervention), 2 
organisms were isolated on microscopy and culture: the S 
aureus found in each case was sensitive to cephalexin but 
the second organism isolated (P aeruginosa in one case and 
Streptococcus C in the other) was not sensitive to cephalexin. 
Ciprofloxacin was introduced for each SSI not responding to 
cephalexin, in accordance with swab sensitivity results.
Discussion
The results of this trial did not show any clinically or statis-
tically significant reduction in the rate of SSI from a single 
dose of cephalexin administered 40-60 minutes before skin 
incision. There was no increase in adverse outcomes related 
to antibiotic administration in the intervention group.
These results contrast to the only previously identified 
study examining the effect of antibiotic prophylaxis in lower 
limb ellipse skin excisions, which showed a reduction in the 
incidence of SSI from a similar baseline rate of 35.7% to a 
Table 4. Comparison of Analgesia Requirements, Adverse Symptoms, Follow-up Treat-
ment, and Swab Results for Intervention and Control Study Participants
Characteristic
Control 
(n = 55)
Intervention 
(n = 55)
P Value
Surgical site infection 17 (30.9%) 14 (25.5%) 0.525
Analgesia requirements (%)
 None
 Strongest paracetamol
 Strongest Panadeinea
 Strongest Panadeine Fortea
 Strongest Endoneb
45 (81.8%)
8 (14.5%)
0
2 (3.6%)
0
43 (78.2%)
11 (20.0%)
0
0
1 (1.8%)
0.329
Adverse symptoms (%)
 Nausea following ingestion of study capsules
 Diarrhea following ingestion of study capsules 
0
0
1 (1.8%)
0
1.0
1.0
Antibiotics started (%)
 None
 Cephalexin
 Dicloxacillin
 Unknown antibiotic started by nonpractice doctor
38 (69.1%)
16 (29.1%)
0
1 (1.8%)
41 (74.5%)
12 (21.8%)
1 (1.8%)
1 (1.8%)
0.753
Swab result (%) (n = 21)
 S aureus sensitive to cephalexin
 S aureus sensitive to cephalexin + 2nd organism  
  not sensitive to cephalexin
 Other organism sensitive to cephalexin
 Other organism not sensitive to cephalexin
 Normal skin flora
8 (%)
1 (%)
0
1 (%)
2 (%)
4 (%)
1 (%)
1 (%)
1 (%)
2 (%)
0.879
a Paracetamol and codeine.
b Oxycodone.
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Conclusions
Despite confirmation that the majority of complex below-
knee closure SSIs responded effectively to oral cephalexin 
postoperatively, we were unable to demonstrate that a single 
preoperative 2-g dose of cephalexin could prevent SSI from 
occurring.
Infection rates for below-knee surgery are unacceptably 
high, even in temperate climates. As antibiotic prophylaxis 
has been shown to be helpful for other dermatological high-
risk areas, further research experimenting with different 
antibiotic prophylactic regimens is worthwhile.
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The recruited cases for this study were at particularly 
high infection risks, and we postulate that this was the reason 
for the failure of antibiotic prophylaxis in our study. First, 
the anatomical site studied was below the knee, which has 
been shown to have higher risk of infection than other ana-
tomical sites [13,16]. Second, only flap and graft surgery was 
included, which is known to be of higher SSI risk than simpler 
surgical techniques [20]. Third, the study was conducted in 
a tropical setting, where infection rates have previously been 
shown to be increased (8.6% and 11.7% in studies in the 
Mackay region) [35,36]. The reason for this remains unclear, 
but might be related to tropical humidity. We hypothesize that 
a single-dose antibiotic prophylaxis was simply insufficient 
in dose and duration to prevent SSI in these circumstances.
Minimizing antibiotic dose and duration is an increasingly 
important focus of research [37]. Given the advantages of 
prophylactic antibiotics in reducing morbidity, and poten-
tially reducing the total amount of antibiotic prescribed [17], 
we would recommend that future research investigate other 
prophylactic regimens, such as larger or multiple pre- or 
perioperative doses of antibiotic or antibiotic mixed with 
local anesthetic and injected directly into the wound site 
preoperatively [38,39].
The strengths of our study were a blind, randomized 
design with placebo control, a standardized protocol for 
excision and follow-up, as well as the collection of a large 
amount of demographic, medical, and excision-related data 
for comparison of groups.
We must, however, acknowledge some limitations to our 
study. Infection may have been underreported, with partici-
pants presenting to doctors outside the study practice after 
surgery. Various characteristics influence SSI, and although 
information on as many variables as possible was recorded, it 
is difficult to ensure that all possible variables are comparable 
at baseline. Despite the intention to take swabs for micros-
copy culture and sensitivity for all cases of clinical SSI, only 
21 swabs were taken in 31 suspected SSI cases.
There may also be limitations to generalizing our find-
ings. This study included complex procedures only, and we 
do not know the effect of this regimen for elliptical excisions 
albeit that few nasal and aural skin cancers can be effectively 
excised with an ellipse. The climate in North Queensland is 
hot and humid, with a mean daily maximum temperature 
ranging between 24.2°C and 30°C during the summer months 
and a relative humidity of 75%-79%. The results may not 
necessarily be generalizable to a temperate climate with a 
lower baseline infection rate.
The diagnosis of infection, even when guidelines are 
used, is subjective, and interobserver and intraobserver 
variation may occur [40]. However, the definition we used is 
the most widely implemented standard definition of wound 
infection [27].
Research  |  Dermatol Pract Concept 2019;9(1):8 35
27. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC 
definitions for nosocomial infections, 1988. Am J Infect Control. 
1988;16(3):128.
28. Altman D, Moher D, Schulz KF; The CONSORT Group. CON-
SORT 2010 Statement. http://www.consort-statement.org/con-
sort-2010. 2014. Accessed June 1, 2018
29. Altman DG. Confidence intervals for the number needed to treat. 
BMJ. 1998;317(7168):1309.
30. Paul SP. “Halo” grafting: a simple and effective technique of skin 
grafting. Dermatol Surg. 2010;36(1):115-119.
31. Amland PF, Andenaes K, Samdal F, et al. A prospective, double-
blind, placebo-controlled trial of a single dose of azithromycin on 
postoperative wound infections in plastic surgery. Plast Reconstr 
Surg. 1995;96(6):1378-1383.
32. Rosengren H, Heal CF, Buttner PG Effect of a single prophylactic 
preoperative oral antibiotic dose on surgical site infection fol-
lowing complex dermatological procedures on the nose and ear: 
a prospective, randomised, controlled, double-blinded trial. BMJ 
Open. 2018;8:e020213.
33. Kuijpers DI, Smeets NWJ, Lapière K, Thissen MRTM, Krekels 
GAM, Neumann HAM. Do systemic antibiotics increase the sur-
vival of a full thickness graft on the nose? J Eur Acad Dermatol 
Venereol. 2006;20(10):1296-1301.
34. Zhang Y, Dong J, Qiao Y, He J, Wang T, Ma S. Efficacy and 
safety profile of antibiotic prophylaxis usage in clean and clean-
contaminated plastic and reconstructive surgery: a meta-analysis 
of randomized controlled trials. Ann Plast Surg. 2014;72(1):121-
130.
35. Heal C, Buettner P, Raasch B, et al. Can sutures get wet? Prospec-
tive randomised controlled trial of wound management in general 
practice. BMJ. 2006;332(7549):1053-1056.
36. Heal C, Buettner P, Cruickshank, et al. Does single application 
of topical chloramphenicol to high risk sutured wounds reduce 
incidence of wound infection after minor surgery? Prospec-
tive randomised placebo controlled double blind trial. BMJ. 
2009;338:a2812.
37. Llewelyn MJ, Fitzpatrick JM, Darwin E, et al. The antibiotic 
course has had its day. BMJ. 2017;358:j3418.
38. Griego RD, Zitelli JA. Intra-incisional prophylactic antibiotics for 
dermatologic surgery. Arch Dermatol. 1998;134(6):688-692.
39. Huether MJ, Griego RD, Brodland DG, Zitelli JA. Clindamycin 
for intraincisional antibiotic prophylaxis in dermatologic surgery. 
Arch Dermatol. 2002;138(9):1145-1148.
40. Bruce J, Russell EM, Mollison J, Krukowski ZH. The quality of 
measurement of surgical wound infection as the basis for monitor-
ing: a systematic review. J Hosp Infect. 2001;49(2):99-108.
12. Wahie S, Lawrence CM. Wound complications following diag-
nostic skin biopsies in dermatology inpatients. Arch Dermatol. 
2007;143(10):1267-1271.
13. Heal C, Buettner P, Browning S. Risk factors for wound in-
fection after minor surgery in general practice. Med J Aust. 
2006;185(5):255-258.
14. Lathlean S. Skin cancer in general practice in South Australia: a 
five year study. Aust Fam Physician. 1999;(28 Suppl 1):S28-S31.
15. Bordeaux JS, Martires KJ, Goldberg D, Pattee SF, Fu P, Maloney 
ME. Prospective evaluation of dermatologic surgery complica-
tions including patients on multiple antiplatelet and anticoagulant 
medications. J Am Acad Dermatol. 2011;65(3):576-583.
16. Heal CF, Buettner PG, Drobetz H. Risk factors for surgical 
site infection after dermatological surgery. Int J Dermatol. 
2012;51(7)796-803.
17. Smith SC, Heal CF, Buttner PG. Prevention of surgical site infec-
tion in lower limb skin lesion excisions with single dose oral an-
tibiotic prophylaxis: a prospective randomised placebo-controlled 
double-blind trial. BMJ Open. 2014;4(7):e005270.
18. Sylaidis P, Wood S, Murray DS. Postoperative infection following 
clean facial surgery. Ann Plast Surg. 1997;39(4):342-346.
19. Rosengren H, Heal C, Smith S. An update on antibiotic prophy-
laxis in dermatologic surgery. Curr Dermatol Rep. 2012;1(2):55-
63.
20. Amici JM, Rogues AM, Lasheras A, et al. A prospective study of 
the incidence of complications associated with dermatological 
surgery. Br J Dermatol. 2005;153(5):967-971.
21. Rossi AM, Mariwalla K. Prophylactic and empiric use of antibiot-
ics in dermatologic surgery: a review of the literature and practical 
considerations. Dermatol Surg. 2012;38(12):1898-1921.
22. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC 
Project Group. Outpatient antibiotic use in Europe and asso-
ciation with resistance: a cross-national database study. Lancet. 
2005;365(9459):579-587.
23. Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of 
antibiotic prescribing in primary care on antimicrobial resistance 
in individual patients: systematic review and meta-analysis. BMJ. 
2010;340:c2096.
24. Moorhead C, Torres A. I PREVENT bacterial resistance: an up-
date on the use of antibiotics in dermatologic surgery. Dermatol 
Surg. 2009;35(10):1532-1538.
25. Burke JP. Maximizing appropriate antibiotic prophylaxis for 
surgical patients: an update from LDS Hospital, Salt Lake City. 
Clin Infect Dis. 2001;33 Suppl 2:S78-S83.
26. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, 
Burke JP. The timing of prophylactic administration of antibi-
otics and the risk of surgical-wound infection. N Engl J Med. 
1992;326(5):281-286.
